What is the mechanism of action of Bosutinib?

Bosutinibis used to treat a certain type of chronic myelogenous leukemia (CML), including in adults recently diagnosed with the disease and in people who no longer benefit from other CML drugs or who cannot take them because of side effects. Bosutinib belongs to the kinase inhibitor class of drugs. It works by blocking the activity of an abnormal protein that signals cancer cells to multiply, which helps stop the spread of cancer cells.

Bosutinib is a tyrosine kinase inhibitor. Bosutinib inhibits the BCR-ABLkinase that promotes chronic myelogenous leukemia. It is also a Src family kinase(IncludingSrc, Lyn and Hck) inhibitors. Bosutinib inhibits 16 of the 18 imatinib-resistant forms of BCR-ABL kinase expressed in murine myeloid cell lines. Bosutinib does not inhibit T315I and V299L mutant cells.

Bosutinib is primarily metabolized byCYP3A4. The major circulating metabolites found in plasma are oxydechlorination (M2) (M2) and bosutinib (19% of maternal exposure) and N-demethylation. >(M5)Bosutinib(25% of maternal exposure), bosutinibN-oxide(M6)are minor circulating metabolites. All metabolites are considered inactive. After a single oral dose of bosutinib, the mean (SD) apparent clearance was 189±48 L/h. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.

xa0